Title |
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
|
---|---|
Published in |
Acta Neuropathologica, June 2012
|
DOI | 10.1007/s00401-012-0998-0 |
Pubmed ID | |
Authors |
Dong-Anh Khuong-Quang, Pawel Buczkowicz, Patricia Rakopoulos, Xiao-Yang Liu, Adam M. Fontebasso, Eric Bouffet, Ute Bartels, Steffen Albrecht, Jeremy Schwartzentruber, Louis Letourneau, Mathieu Bourgey, Guillaume Bourque, Alexandre Montpetit, Genevieve Bourret, Pierre Lepage, Adam Fleming, Peter Lichter, Marcel Kool, Andreas von Deimling, Dominik Sturm, Andrey Korshunov, Damien Faury, David T. Jones, Jacek Majewski, Stefan M. Pfister, Nada Jabado, Cynthia Hawkins |
Abstract |
Pediatric glioblastomas (GBM) including diffuse intrinsic pontine gliomas (DIPG) are devastating brain tumors with no effective therapy. Here, we investigated clinical and biological impacts of histone H3.3 mutations. Forty-two DIPGs were tested for H3.3 mutations. Wild-type versus mutated (K27M-H3.3) subgroups were compared for HIST1H3B, IDH, ATRX and TP53 mutations, copy number alterations and clinical outcome. K27M-H3.3 occurred in 71 %, TP53 mutations in 77 % and ATRX mutations in 9 % of DIPGs. ATRX mutations were more frequent in older children (p < 0.0001). No G34V/R-H3.3, IDH1/2 or H3.1 mutations were identified. K27M-H3.3 DIPGs showed specific copy number changes, including all gains/amplifications of PDGFRA and MYC/PVT1 loci. Notably, all long-term survivors were H3.3 wild type and this group of patients had better overall survival. K27M-H3.3 mutation defines clinically and biologically distinct subgroups and is prevalent in DIPG, which will impact future therapeutic trial design. K27M- and G34V-H3.3 have location-based incidence (brainstem/cortex) and potentially play distinct roles in pediatric GBM pathogenesis. K27M-H3.3 is universally associated with short survival in DIPG, while patients wild-type for H3.3 show improved survival. Based on prognostic and therapeutic implications, our findings argue for H3.3-mutation testing at diagnosis, which should be rapidly integrated into the clinical decision-making algorithm, particularly in atypical DIPG. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | <1% |
United States | 2 | <1% |
Australia | 1 | <1% |
Czechia | 1 | <1% |
Ukraine | 1 | <1% |
Netherlands | 1 | <1% |
Korea, Republic of | 1 | <1% |
France | 1 | <1% |
Japan | 1 | <1% |
Other | 1 | <1% |
Unknown | 558 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 99 | 17% |
Researcher | 90 | 16% |
Student > Bachelor | 60 | 11% |
Student > Master | 49 | 9% |
Student > Doctoral Student | 40 | 7% |
Other | 98 | 17% |
Unknown | 134 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 124 | 22% |
Biochemistry, Genetics and Molecular Biology | 122 | 21% |
Agricultural and Biological Sciences | 92 | 16% |
Neuroscience | 23 | 4% |
Chemistry | 9 | 2% |
Other | 45 | 8% |
Unknown | 155 | 27% |